GLP-1R — Drug Target
All drugs that target GLP-1R — marketed and clinical-stage. Includes 2 drug classes acting on this target.
Drug classes
GLP-1 receptor agonist · GLP-1 receptor agonist and long-acting basal insulin analog
Marketed (24)
- Liraglutide injection · Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca · GLP-1 receptor agonist · Diabetes; Obesity
Liraglutide activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby reducing blood glucose and promoting weight loss. - Benaglutide Injection · The Affiliated Hospital of Qingdao University · GLP-1 receptor agonist · Diabetes
Benaglutide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. - Exenatide twice daily (BID) · Eli Lilly and Company · GLP-1 receptor agonist · Diabetes
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. - Victoza (liraglutide) · Zealand University Hospital · GLP-1 receptor agonist · Diabetes
Victoza activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. - exenatide (Byetta) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · GLP-1 receptor agonist · Diabetes
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. - Liraglutide+standard-of-care treatment · Second Affiliated Hospital, School of Medicine, Zhejiang University · GLP-1 receptor agonist · Diabetes
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion, suppress glucagon, and slow gastric emptying, used here in combination with standard diabetes care. - GLP-1 receptor agonist · Brigham and Women's Hospital · GLP-1 receptor agonist · Diabetes
GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon release, and slow gastric emptying, thereby lowering blood glucose levels. - Semaglutide Pen Injector [Ozempic] · University of Nottingham · GLP-1 receptor agonist · Diabetes
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. - GLP-1 RAs · Shanghai 10th People's Hospital · GLP-1 receptor agonist · Endocrinology / Diabetes
GLP-1 receptor agonists activate the glucagon-like peptide-1 receptor to enhance insulin secretion, suppress glucagon release, and slow gastric emptying, thereby reducing blood glucose levels. - dulaglutide injection · First Affiliated Hospital of Zhejiang University · GLP-1 receptor agonist · Diabetes
Dulaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce glucagon release in response to elevated blood glucose. - Semaglutide Injectable Product · Neurogastrx, Inc. · GLP-1 receptor agonist · Diabetes, Obesity
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss. - Exenatide once weekly (QW) · Eli Lilly and Company · GLP-1 receptor agonist · Diabetes
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. - Byetta (Exenatide) · Beijing Chao Yang Hospital · GLP-1 receptor agonist · Diabetes
Exenatide mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion in response to blood glucose elevation and suppress glucagon release. - sub cutaneous liraglutide · Yaounde Central Hospital · GLP-1 receptor agonist · Diabetes
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying. - NovoHelisen Depot · Wroclaw Medical University · GLP-1 receptor agonist · Diabetes
NovoHelisen Depot is a long-acting formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist. - Liraglutide Pen Injector [Victoza] · Imperial College London · GLP-1 receptor agonist · Diabetes
Liraglutide activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels. - GLP1 receptor agonist · Weill Medical College of Cornell University · GLP-1 receptor agonist · Diabetes
GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels. - Semaglutide Pen Injector · University of Pennsylvania · GLP-1 receptor agonist · Diabetes, Obesity
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. - liraglutide monotherapy · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · GLP-1 receptor agonist · Diabetes
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying in response to elevated blood glucose. - Lixisenatide (AVE0010) · Sanofi · GLP-1 receptor agonist · Diabetes
Lixisenatide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. - Liraglutide + Exercise training · University of Virginia · GLP-1 receptor agonist · Diabetes
Liraglutide activates GLP-1 receptors to enhance insulin secretion and reduce appetite, while exercise training improves insulin sensitivity and cardiovascular fitness through physical conditioning. - Semaglutide Treatment · University Health Network, Toronto · GLP-1 receptor agonist · Endocrinology
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. - Receptor Agonists (GLP1RA) · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · GLP-1 receptor agonist · Diabetes
GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels. - Dulaglutide Pen · Eli Lilly and Company · GLP-1 receptor agonist · Diabetes
Dulaglutide activates GLP-1 receptors on pancreatic beta cells to increase insulin secretion and suppress glucagon in response to elevated blood glucose.
Phase 3 pipeline (85)
- DWP14012 · Daewoong Pharmaceutical Co. LTD. · GLP-1 receptor agonist · Endocrinology / Diabetes
DWP14012 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - Ecnoglutide High Dosage · Hangzhou Sciwind Biosciences Co., Ltd. · GLP-1 receptor agonist · Diabetes
Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control. - GC5107 · GC Biopharma Corp · GLP-1 receptor agonist · Endocrinology
GC5107 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion and reduces glucagon release to lower blood glucose levels. - HCP1701 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Endocrinology / Diabetes
HCP1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - JKN2401 Injection · Joincare Pharmaceutical Group Industry Co., Ltd · GLP-1 receptor agonist · Endocrinology / Diabetes
JKN2401 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. - GB242 · Genor Biopharma Co., Ltd. · GLP-1 receptor agonist · Diabetes
GB242 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. - HGP1909 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
HGP1909 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - HGP1201 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Endocrinology / Diabetes
HGP1201 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - Drug: Semaglutide Administered SC · BrightGene Bio-Medical Technology Co., Ltd. · GLP-1 receptor agonist · Diabetes, Obesity, Cardiovascular
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, suppress appetite, and promote weight loss. - SYR-322-MET · Takeda · GLP-1 receptor agonist · Diabetes
SYR-322-MET is a glucagon-like peptide-1 (GLP-1) receptor agonist. - DWP16001 · Daewoong Pharmaceutical Co. LTD. · GLP-1 receptor agonist · Endocrinology / Diabetes
DWP16001 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - Exenatide infusion · Amsterdam UMC, location VUmc · GLP-1 receptor agonist · Diabetes
Exenatide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce blood glucose in response to meals. - HPP2202 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
HPP2202 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - HCP2102-2 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
HCP2102-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. - semaglutide injection (HD1916) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · GLP-1 receptor agonist · Diabetes
Semaglutide injection works by mimicking the action of a natural hormone in the body called glucagon-like peptide-1 (GLP-1) to help lower blood sugar levels. - HU-014 Inj · Huons Co., Ltd. · GLP-1 receptor agonist · Diabetes
HU-014 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. - Gradual dose reduction of semaglutide · Mount Sinai Hospital, Canada · GLP-1 receptor agonist · Endocrinology / Obesity
Gradual dose reduction of semaglutide investigates the effects of tapering a GLP-1 receptor agonist to assess weight maintenance, metabolic outcomes, and safety upon discontinuation. - JK-1201I · JenKem Technology Co., Ltd. · GLP-1 receptor agonist · Endocrinology/Metabolic Disease
JK-1201I is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. - Liraglutide Pen Injector · University of North Carolina, Chapel Hill · GLP-1 receptor agonist · Diabetes
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying. - HIP1402 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
HIP1402 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - BYETTA treatment · Assistance Publique Hopitaux De Marseille · GLP-1 receptor agonist · Diabetes
Byetta (exenatide) is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion in response to elevated blood glucose levels. - HPP2101 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
HPP2101 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. - DWP712 inj. · Daewoong Pharmaceutical Co. LTD. · GLP-1 receptor agonist · Diabetes
DWP712 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. - HPP2104-2 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
HPP2104-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. - Semaglutide(Wegovy® ) · Gan & Lee Pharmaceuticals. · GLP-1 receptor agonist · Diabetes
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels. - Sevre-Long™ · Mundipharma Medical Company · GLP-1 receptor agonist · Diabetes
Sevre-Long™ is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to regulate glucose metabolism. - Lyophilized albiglutide DCC pen injector · GlaxoSmithKline · GLP-1 receptor agonist · Diabetes
Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to lower blood glucose levels. - Abrupt cessation of semaglutide · Mount Sinai Hospital, Canada · GLP-1 receptor agonist · Diabetes
Abrupt cessation of semaglutide involves the sudden discontinuation of a GLP-1 receptor agonist, which may result in rapid changes in glucose metabolism and metabolic rebound effects. - ABBV-951 · AbbVie · GLP-1 receptor agonist · Endocrinology/Metabolic Disease
ABBV-951 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. - HCP1401 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Endocrinology
HCP1401 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - Venglustat GZ402671 · Sanofi · GLP-1 receptor agonist · Diabetes
Venglustat is a selective and reversible inhibitor of glucosylceramidase. - NNC0365-3769 (Mim8) PPX · Novo Nordisk A/S · GLP-1 receptor agonist · Diabetes
Mim8 PPX is a glucagon-like peptide-1 (GLP-1) receptor agonist. - Placebo II (Semaglutide) · Novo Nordisk A/S · GLP-1 receptor agonist · Diabetes, Obesity
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss. - HPP2103-1 · Hanmi Pharmaceutical Company Limited · GLP-1 receptor agonist · Diabetes
HPP2103-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release. - LY900003 · Eli Lilly and Company · GLP-1 receptor agonist · Endocrinology
LY900003 is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose and promote weight loss. - Semaglutide B · Novo Nordisk A/S · GLP-1 receptor agonist · Diabetes
Semaglutide B is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels. - STR001-IT and STR001-ER · Strekin AG · GLP-1 receptor agonist · Diabetes
STR001-IT and STR001-ER are glucagon-like peptide-1 (GLP-1) receptor agonists. - YM177 · Astellas Pharma Inc · GLP-1 receptor agonist · Diabetes
YM177 is a glucagon-like peptide-1 (GLP-1) receptor agonist. - albiglutide + insulin glargine · GlaxoSmithKline · GLP-1 receptor agonist and long-acting basal insulin analog · Diabetes
Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, and insulin glargine is a long-acting basal insulin analog that provides a steady level of insulin throughout the day. - Umkamin(Active Comparator) · Hanlim Pharm. Co., Ltd. · GLP-1 receptor agonist · Diabetes
Umkamin is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Phase 2 pipeline (6)
- GLP-1 analogs · Canadian Network for Observational Drug Effect Studies, CNODES · GLP-1 receptor agonist · Diabetes
GLP-1 analogs mimic the action of the hormone glucagon-like peptide-1 to regulate blood sugar levels. - Dulaglutide,QW · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · GLP-1 receptor agonist · Diabetes
GLP-1 receptor agonist - GSK2798745 solution · GlaxoSmithKline · GLP-1 receptor agonist · Diabetes
GSK2798745 solution is a glucagon-like peptide-1 (GLP-1) receptor agonist. - Albiglutide weekly injection · GlaxoSmithKline · GLP-1 receptor agonist · Diabetes
GLP-1 receptor agonist - Cotadutide 600 micrograms · AstraZeneca · GLP-1 receptor agonist · Diabetes
Cotadutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels. - Efluelda® Pre-filled syringe · Sanofi · GLP-1 receptor agonist · Diabetes
Efluelda is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels.
Phase 1 pipeline (2)
- Albiglutide Lyophilized DCC Pen Injector · GlaxoSmithKline · GLP-1 receptor agonist · Diabetes
GLP-1 receptor agonist - Arm 5- Tirzepatide · Lexaria Bioscience Corp. · GLP-1 receptor agonist · Diabetes
GLP-1 receptor agonist